In vitro/in vivo assessment of novel 99mTc-bombesin conjugates in human cancer tissue [abstract] by Heinzke, Laura et al.
Laura Heinzke, Chemistry and Biology 
 
Year in School:  Junior 
Hometown: Hazelwood, MO 
Faculty Mentor: Dr. Charles J. Smith, Radiology 
Funding Source: Harry S. Truman Memorial VA Hospital 
 
In vitro/in vivo assessment of novel 99mTc-bombesin conjugates in 
human cancer tissue 
Laura Heinzke, Adam Prasanphanich, Stephanie Lane, Lauren Retzloff, Tammy 
Rold, Gary Sieckman, Timothy Hoffman, & Charles J. Smith 
 
Receptor-specific, radiolabeled peptides are becoming increasingly popular as 
targeting vectors for the development of new diagnostic radiopharmaceuticals. The 
over-expression of certain receptors such as the gastrin releasing peptide receptor 
(GRPr) on human cancer cells makes this method of drug development a viable tool 
for tumor targeting in vivo. Breast, pancreatic, prostate, gastric, colon, and small-
cell lung cancer have demonstrated GRPr expression. In this project, we have 
conjugated a diaminoproionic acid (DPR) bifunctional chelator to bombesin (BBN) 
peptide targeting vector by solid phase peptide synthesis. BBN is an analogue of 
human gastrin releasing peptide (GRP) that binds to the GRPr with high affinity and 
specificity. Conjugates of the general structure [DPR-(X)-BBN(7-14)NH2] (X = a 
series of amino acid pharmacokinetic modifiers) were purified by reverse-phase 
high-performance liquid chromatography and characterized by electrospray-
ionization mass spectrometry. Radiolabeling investigations of with fac-
[99mTc(CO)3(H2O)3]+ (Isolink®) provided for metallated conjugates of the 
following general structure: [99mTc(CO)3-DPR-(X)-BBN(7-14)NH2]. These new 
conjugates demonstrated the ability to target specific human tumors in rodent 
models. Subsequent radiolabeling studies of [DPR-(X)-BBN(7-14)NH2] with fac-
[188Re(CO)3(H2O)3]+, the therapeutic surrogate precursor of Tc-99m, have given 
us the potential to treat specific human tumors via these new targeting vectors. 
Detailed radiolabeling protocols, in vitro cell binding studies, and in vivo 
biodistribution assays will be reported. 
